Skip to Content

Oncovin (vincristine) Disease Interactions

There are 8 disease interactions with Oncovin (vincristine):

Major

Vinca alkaloids (applies to Oncovin) pulmonary dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids. These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose. Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction. Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids. In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.

References

  1. "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome, Research Triangle Pk, NC.
  2. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Velban (vinblastine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Vincristine (applies to Oncovin) neurologic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Neurologic Disorder, Peripheral Neuropathy

The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome. Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential. Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported. Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy. Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.

References

  1. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993): 23-7
  2. Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973): 699-702
  3. Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972): 1369-70
  4. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  5. Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978): 610-2
  6. Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992): 370-3
  7. Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973): 782-3
  8. Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982): 1285-8
  9. Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992): 1260-2
  10. Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985): 637
  11. Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974): 733-7
  12. Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973): 1312
View all 12 references
Moderate

Vincristine (applies to Oncovin) constipation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

Vincristine can cause constipation. Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred. When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.

Moderate

Vincristine (applies to Oncovin) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Vincristine is primarily metabolized by the liver. The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated. Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials. Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity. Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function. Close clinical monitoring of hepatic function is recommended.

References

  1. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Jackson DV, Jr Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978): 101-7
  3. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982): 215-9
Moderate

Vincristine (applies to Oncovin) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine. Clinical monitoring of hematopoetic function is recommended.

References

  1. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Vincristine (applies to Oncovin) myelosuppression

Moderate Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever

Vincristine induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts prior to each dose. If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.

References

  1. Chong CD Logothetis CJ Savaraj N Fritsche HA Gietner AM Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients." J Clin Pharmacol 28 (1988): 714-8
  2. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
  3. Neville AJ Rand CA Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982): 32-8
  4. Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984): 43-5
View all 4 references
Moderate

Vincristine (applies to Oncovin) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated. Caution and monitoring of renal function is advised in patients with renal impairment.

Moderate

Vincristine (applies to Oncovin) SIADH

Moderate Potential Hazard, Low plausibility.

A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine. Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.

References

  1. Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971): 269-71
  2. Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972): 1010-2
  3. Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994): 1199-200
  4. "Product Information. Oncovin (vincristine)." Lilly, Eli and Company, Indianapolis, IN.
View all 4 references

Oncovin (vincristine) drug interactions

There are 375 drug interactions with Oncovin (vincristine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.